ACLX

ACLX ARQT Biotechnology BSX ELAN MASI RGEN SYK TMO Uncategorized WELL

Baron Health Care Fund adds TMO, ARQT, and ELAN; exits Cidara Therapeutics MASI among Q4 moves

Mar 6, 2026

ACLX Biotechnology GILD JNJ LEGN ONeil Trader Uncategorized

What Gilead Is Getting Through The Acquisition Of Arcellx

Feb 23, 2026

ACLX ASH Biotechnology GILD JNJ LEGN Uncategorized

Legend Biotech Arcellx rise after FDA draft guidance on multiple myeloma trials

Jan 20, 2026

ACLX Biotechnology GILD JNJ Uncategorized

Arcellx a new overweight at Wells Fargo on promise of multiple myeloma CAR-T asset

Dec 22, 2025